Serous carcinoma—TP53 (56.5%), BRCA2 (5.8%) and RAD51C (5.8%); endometrioid carcinoma—TP53 (15.4%), ATM (12.8%) and MSH2 (7.7%); clear cell carcinoma—MUTYH (9.4%), TP53 (4.7%), BRCA2 (3.1%) and ERCC8 (3.1%). This evidence concerns the gene TP53 and serous adenocarcinoma.